Jiangsu Hualan New Pharmaceutical Material (301093.SZ) plans to invest 450 million yuan to increase its stake in Lingqing Technology to enhance its strategic layout in the AI pharmaceutical field.

Jiangsu Hualan New Pharmaceutical Material (301093.SZ) announced that the board of directors has approved the "Proposal for Capital Increase to Wholly-owned Subsidiary". Hainan Lingqing Artificial Intelligence Pharmaceutical Technology Co., Ltd. (referred to as "Lingqing Artificial Intelligence") is a wholly-owned subsidiary of the company, and is an important business layout platform for the company in the AI pharmaceutical field. It mainly focuses on artificial intelligence innovation drug research and development solutions and services, helping to promote the research, development, and commercialization of artificial intelligence technology in drug research and industrial applications. The company will increase the capital of the wholly-owned subsidiary Lingqing Artificial Intelligence with its own funds of 450 million yuan. The announcement stated that this capital increase will help the company further improve its strategic layout in the field of AI pharmaceuticals, strengthen the company's continuous investment and industrial synergy capabilities in relevant cutting-edge technology fields, and promote the steady development and commercialization of the company's AI pharmaceutical business.